Navigation Links
New Scientific Studies Show Further Evidence of Avandia Dangers
Date:2/4/2010

Two independent studies document serious medical risks associated with use of popular GlaxoSmithKline diabetes drug

Mineola, NY (Lexis Nexis) February 4, 2010 -- Pharmaceutical giant GlaxoSmithKline is about to suffer more setbacks in the ongoing battle of opinions concerning the safety of its much touted diabetes drug Avandia, according to Marc Grossman, senior partner of leading national personal injury law firm of Sanders Viener Grossman, LLP, in Mineola, N.Y.

The American Diabetes Association has accepted for publication in its prestigious medical journal, Diabetes Care, a study by Harvard researchers that shows users of the diabetes drug Avandia have more than double the risk of a heart attack compared to other diabetes drugs. Further, a jointly sponsored study by both GlaxoSmithKline and i3 Drug Safety, an independent drug-safety firm, will appear in the journal Clinical Therapeutics, showing that Avandia users have a 35-41% increased risk of a heart attack over users of Actos©, Avandia's main competitor.

These findings are the latest in a series of published studies that indicate Avandia users are at an unacceptably increased risk of a heart attack. In 2007, the Food and Drug Administration required a "Black Box" warning be added to Avandia's label about the heart risks associated with drug, but allowed the product to remain on the market even though numerous Endocrinologists and other diabetes experts called for its removal from the market like the other ill-fated drugs Vioxx and Rezulin.

The Harvard group analyzed clinical care data taken from the electronic medical records of patients at several Boston area hospitals and clinics associated with Harvard Medical School. All 26,375 patients records reviewed included a diagnosis of Diabetes and the use of at least one oral diabetic medication used between years 2000 and 2006. The researchers then reviewed the records for all patients who suffered "Myocardial Infarction" or heart attack. The incidence of heart attack was more than double for Avandia compared to its competitor Actos. The researchers chose Avandia to confirm their methodology because of its known "…relative adverse cardiovascular risk profile…" The GlaxoSmithKline-i3 study analyzed health-insurance data from July of 2000 through March of 2007 for 2 groups of 47,501 subjects each; one group using Avandia and the other Actos.

Almost 13,000 former Avandia users who have suffered heart attacks and other significant injuries have filed claims against GlaxoSmithKline in both Federal and State courts.

"This study adds to the overwhelming evidence that Avandia causes heart attacks in an already vulnerable population and it further confirms the basis of these lawsuits," said Marc Grossman, a New York attorney who represents hundreds of former Avandia users in Federal Court in Philadelphia. "It's very disturbing to see what appears to be a pattern of pharmaceutical corporations placing profits ahead of people. The recent studies raise serious questions about the health risks associated with Avandia, yet GSK continues to shirk its responsibility to the thousands of victims of Avandia whose lives are ruined or lost."

The Sanders Firm is a National Law Firm and has recovered over $500 Million for its clients, including thousands of victims of defective drugs and products. For further information or press inquiries, please contact Marc Grossman at 1-800-FAIR-PLAY, via email at mgrossman(at)thesandersfirm(dot)com or go to www.thesandersfirm.com.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3563424.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009
2. The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
3. American Scientific Resources 2009 Annual Meeting of Shareholders Adjourned
4. American Scientific CE Removed - Now Current Information
5. Lung Cancer Foundation of America Gives the Gift of Life This Holiday Season: Announces Inaugural $125,000 Scientific Research Grant
6. Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases
7. Scientific panel evaluates soy infant formula safety
8. The Concord Grape Commands Attention at Major Scientific Conference
9. Patriot Scientific Corporation Announces New Director
10. Wednesday, Dec. 2: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
11. Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientifics PureWeb Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... therapy products, announced today the introduction of the newly designed, innovative shoulder wrap. ... and better cold therapy coverage for the injured arm and shoulder to promote ...
(Date:2/9/2016)... ... ... Shark Finds and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro are pleased ... newly patented product that has solved some of the basic problems golfers have faced since ... or right after a rain shower, might understand the struggle of placing the club down ...
(Date:2/8/2016)... ... 2016 , ... Coast Dental has a new way to help parents keep ... family dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February 19 ... Target at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have healthy ...
(Date:2/8/2016)... , ... February 08, 2016 , ... If you are ... to handle, you are not alone. According to the Center for Disease Control and ... stroke, type 2 diabetes and certain types of cancer, some of the leading causes ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... FRANCISCO , February 9, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, ... be a featured presenting company at Source Capital Group,s ... on February 10-11, 2016 in New York ... on Wednesday, February 10, 2016 at 12:30 pm by ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
(Date:2/9/2016)... -- The leader in accelerated orthodontics, OrthoAccel ® ... recipient of the 2015 Townie Choice Award in the ... device that speeds up orthodontic tooth movement by as ... with treatment, AcceleDent was selected by orthodontists from across ... survey of the most reliable and reputable products ...
Breaking Medicine Technology: